PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections

19:08 EST 22nd December 2014 | BioPortfolio

Summary

Primary

- To evaluate the efficacy of Pulmonaron in the decrease of interleukin-4/interferon gamma after second period of treatment

Secondary

- To evaluate the efficacy of Pulmonarom in the prevention of upper respiratory tract infections symptoms through patient evaluation of fever or respiratory presence after second period of treatment

- To evaluate loss of working or study days after second period of treatment

- To evaluate the safety and tolerability of Pulmonarom in the population under study

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Respiratory Tract Infections

Intervention

Bacterial Lysates, placebo

Location

Sanofi-Aventis Administrative Office
Col. Coyoacan
Mexico

Status

Completed

Source

Sanofi-Aventis

Results (where available)

View Results

Links

Clinical Trials [952 Associated Clinical Trials listed on BioPortfolio]

Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections

To assess effectiveness of Trulimax (Azithromycin) in Acute Bacterial Upper Respiratory Tract Infections (URTIs).

Outpatient Registry Trial of Respiratory Tract Infections in Adults

To measure the speed of bacterial eradication from the respiratory tract after administration of azithromycin or telithromycin.

A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections

The specific objectives of this investigation are to assess the effectiveness of daily gargling and vitamin D supplementation as preventative measures against incident upper respiratory tr...

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study (ADMA 001) is to evaluate the safety and efficacy of RI-...

CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study

The purpose of this study is to assess the efficacy and safety of J022X ST for prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) compared to placebo in children of younger...

PubMed Articles [11426 Associated PubMed Articles listed on BioPortfolio]

Oxygen therapy for lower respiratory tract infections in children between 3 months and 15 years of age.

Treatment for lower respiratory tract infections (LRTIs) includes administering complementary oxygen. The effectiveness of oxygen therapy and of different delivery methods remains uncertain.

Children with respiratory infections - How and when to perform anesthesia.

Infections of the upper respiratory tract ( URI) are the most common preoperative encountered comorbidity in childhood. Whether anesthesia for a child with respiratory infection should be performed or...

Infections and use of antibiotics in residents of long-term care facilities in Hungary.

Introduction: Healthcare associated infections and antimicrobial use are common among residents of long-term care facilities. Faced to the lack of standardized data, the European Centre for Disease Pr...

Potential respiratory pathogens colonisation of the denture plaque of patients with chronic obstructive pulmonary disease.

The role of bacterial infections in acute exacerbations of chronic obstructive pulmonary disease (COPD) is widely examined. Denture plaque in patients with COPD is an example of bacterial and fungal b...

Divergent Functions of Toll-Like Receptors during Bacterial Lung Infections.

Lower respiratory tract infections caused by bacteria are a major cause of death in humans irrespective of gender, race, or geography. Indeed, accumulated data indicate greater mortality and morbidity...

Medical and Biotech [MESH] Definitions

A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.

The expelling of bacteria from the body. Important routes include the respiratory tract, genital tract, and intestinal tract.

Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.

Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.

An abnormal passage communicating between any component of the respiratory tract or between any part of the respiratory system and surrounding organs.

More From BioPortfolio on "PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Advertisement